Potential subtype-specific therapeutic approaches in small cell lung cancer

Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer

(2023) Zsuzsanna Valko et al.   BRITISH JOURNAL OF CANCER

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

(2023) Zsolt Megyesfalvi et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

(2023) Charles M. Rudin et al.   Journal of Hematology & Oncology

De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways

(2023) Subhamoy Chakraborty et al.   CLINICAL CANCER RESEARCH

Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions

(2023) Chenyue Zhang et al.   Journal of Translational Medicine

Cancer statistics, 2022

(2022) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter study

(2022) Zsolt Megyesfalvi et al.   JOURNAL OF PATHOLOGY

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

(2022) L. Paz-Ares et al.   ESMO Open

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

(2021) Carl M. Gay et al.   CANCER CELL

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

(2021) Stephen V. Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

The landscape of small cell lung cancer metastases: Organ specificity and timing

(2021) Zsolt Megyesfalvi et al.   Thoracic Cancer

Molecular profiles of small cell lung cancer subtypes: therapeutic implications

(2021) Anna Schwendenwein et al.   Molecular Therapy-Oncolytics

Small-cell lung cancer in never-smokers

(2021) M. Torres-Durán et al.   ESMO Open

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

(2021) Apar Kishor P. Ganti et al.   Journal of the National Comprehensive Cancer Network

New Approaches to SCLC Therapy: From the Laboratory to the Clinic

(2020) John T. Poirier et al.   Journal of Thoracic Oncology

Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization

(2020) Marina K. Baine et al.   Journal of Thoracic Oncology

Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States

(2020) David A. Siegel et al.   JAMA Oncology

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study

(2019) Daniel Morgensztern et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

(2019) Taofeek K. Owonikoko et al.   Journal of Thoracic Oncology

POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer

(2018) Yu-Han Huang et al.   GENES & DEVELOPMENT

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

(2018) M. Catherine Pietanza et al.   JOURNAL OF CLINICAL ONCOLOGY

Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition

(2018) Deshui Jia et al.   Cancer Discovery

The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications

(2018) Wanyin Lim et al.   QUANTITATIVE IMAGING IN MEDICINE AND SURGERY

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

(2018) Taofeek K. Owonikoko et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer

(2014) Neelesh Sharma et al.   INVESTIGATIONAL NEW DRUGS

Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer

(2013) J. T. Poirier et al.   JNCI-Journal of the National Cancer Institute

Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial

(2011) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY